Skip to Main Content
Back to News

Lobbying Update: $450,000 of CARDINAL HEALTH INC lobbying was just disclosed

None

$450,000 of CARDINAL HEALTH INC lobbying was just disclosed, from Q2 of 2025, in a new Lobbying Disclosure Act filing.

This included lobbying on issues like:

"Issues related to tariffs, trade, and U.S. trade policy. Issues related to drug pricing, pharmacies, provider status, biosimilars, cell and gene therapy, food is medicine; Issues related to provider reimbursement, Medicare and Medicaid, workforce shortages, and product shortages. Education on supply chain issues, drug shortages, domestic manufacturing, medical device environmental issues; Issues related to the medical supply chain and transportation. Issues related to tax reform and 2017 Tax Cuts and Jobs Act. Issues related to tariffs, trade, and U.S. trade policy."

You can find more data on corporate lobbying on Quiver Quantitative.

CAH Congressional Stock Trading

Members of Congress have traded $CAH stock 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $CAH stock by members of Congress over the last 6 months:

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

CAH Insider Trading Activity

CAH Insider Trades

CAH insiders have traded $CAH stock on the open market 19 times in the past 6 months. Of those trades, 0 have been purchases and 19 have been sales.

Here’s a breakdown of recent trading of $CAH stock by insiders over the last 6 months:

  • JASON M. HOLLAR (Chief Executive Officer) has made 0 purchases and 5 sales selling 143,606 shares for an estimated $21,424,215.
  • AARON E ALT (Chief Financial Officer) has made 0 purchases and 2 sales selling 48,243 shares for an estimated $7,177,389.
  • STEPHEN M MASON (CEO, GMPD Segment) has made 0 purchases and 3 sales selling 41,575 shares for an estimated $6,187,063.
  • JESSICA L MAYER (Chief Legal/Compliance Officer) has made 0 purchases and 3 sales selling 38,078 shares for an estimated $5,666,832.
  • OLA M SNOW (Chief Human Resources Officer) has made 0 purchases and 2 sales selling 28,151 shares for an estimated $4,192,916.
  • DEBORAH WEITZMAN (CEO, PSS Segment) sold 21,367 shares for an estimated $3,216,374
  • MICHELLE D. GREENE (Chief Information Officer) has made 0 purchases and 2 sales selling 13,500 shares for an estimated $2,009,043.
  • MARY C. SCHERER (Chief Accounting Officer) sold 6,766 shares for an estimated $1,009,825

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

CAH Hedge Fund Activity

We have seen 581 institutional investors add shares of CAH stock to their portfolio, and 529 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

  • FMR LLC added 2,271,634 shares (+56.7%) to their portfolio in Q2 2025, for an estimated $381,634,512
  • CITADEL ADVISORS LLC removed 1,798,782 shares (-63.1%) from their portfolio in Q2 2025, for an estimated $302,195,376
  • JPMORGAN CHASE & CO removed 1,653,607 shares (-39.6%) from their portfolio in Q2 2025, for an estimated $277,805,976
  • NORGES BANK added 1,392,384 shares (+66.7%) to their portfolio in Q2 2025, for an estimated $233,920,512
  • BLACKROCK, INC. removed 1,276,568 shares (-4.0%) from their portfolio in Q2 2025, for an estimated $214,463,424
  • AMUNDI removed 1,183,078 shares (-62.2%) from their portfolio in Q2 2025, for an estimated $198,757,104
  • LSV ASSET MANAGEMENT removed 849,442 shares (-46.4%) from their portfolio in Q2 2025, for an estimated $142,706,256

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

CAH Analyst Ratings

Wall Street analysts have issued reports on $CAH in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

  • Leerink Partners issued a "Outperform" rating on 08/12/2025
  • Morgan Stanley issued a "Overweight" rating on 07/16/2025
  • Evercore ISI Group issued a "Outperform" rating on 06/12/2025
  • B of A Securities issued a "Buy" rating on 06/10/2025
  • Wells Fargo issued a "Overweight" rating on 06/03/2025
  • UBS issued a "Buy" rating on 05/02/2025
  • Baird issued a "Outperform" rating on 05/02/2025

To track analyst ratings and price targets for CAH, check out Quiver Quantitative's $CAH forecast page.

CAH Price Targets

Multiple analysts have issued price targets for $CAH recently. We have seen 8 analysts offer price targets for $CAH in the last 6 months, with a median target of $185.5.

Here are some recent targets:

  • Stephen Baxter from Wells Fargo set a target price of $185.0 on 08/13/2025
  • Elizabeth Anderson from Evercore ISI Group set a target price of $190.0 on 08/13/2025
  • Eric Coldwell from Baird set a target price of $203.0 on 08/13/2025
  • Michael Cherny from Leerink Partners set a target price of $186.0 on 08/12/2025
  • Erin Wright from Morgan Stanley set a target price of $190.0 on 07/16/2025
  • Daniel Grosslight from Citigroup set a target price of $170.0 on 06/13/2025
  • Michael Cherny from B of A Securities set a target price of $170.0 on 06/10/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles